REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

RegenXBio shared additional interim data from their Phase 1/2 AAV micro-dystrophin gene therapy clinical trial for individuals with Duchenne aged 4-11 years old. The first participant in dose level 2, aged 12 years old, demonstrated 75.7% micro-dystrophin expression at 3 months. RegenXBio also shared video recordings of treated participants to indicate initial evidence of strength and functional improvements. RegenXBio plans to share complete strength and functional data for both dose levels and initiate a pivotal trial in the second half of this year.  

READ THE PRESS RELEASE HERE